Pfizer Inc. (NYSE:PFE) Position Trimmed by Community Bank & Trust Waco Texas

Community Bank & Trust Waco Texas lessened its position in Pfizer Inc. (NYSE:PFE) by 37.8% in the 4th quarter, Holdings Channel reports. The fund owned 84,446 shares of the biopharmaceutical company’s stock after selling 51,353 shares during the period. Community Bank & Trust Waco Texas’ holdings in Pfizer were worth $2,431,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Invesco Ltd. raised its stake in shares of Pfizer by 30.9% in the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after acquiring an additional 5,678,004 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Pfizer by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after acquiring an additional 5,185,453 shares during the last quarter. Bank of Nova Scotia grew its position in shares of Pfizer by 219.4% during the 3rd quarter. Bank of Nova Scotia now owns 5,503,983 shares of the biopharmaceutical company’s stock worth $182,567,000 after buying an additional 3,780,696 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in shares of Pfizer by 38.9% during the 3rd quarter. Canada Pension Plan Investment Board now owns 10,028,940 shares of the biopharmaceutical company’s stock worth $332,660,000 after buying an additional 2,807,846 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Trading Down 0.8 %

NYSE PFE traded down $0.20 during trading on Wednesday, hitting $26.12. The stock had a trading volume of 8,342,911 shares, compared to its average volume of 41,676,766. The company has a market capitalization of $147.91 billion, a PE ratio of 72.72, a PEG ratio of 1.18 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average price of $27.07 and a 200 day moving average price of $28.52. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. The firm’s revenue was down 41.3% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.